Clinical Trial Update: Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing Prevenar (PCV13) with Pneumovax 23 in reducing pneumococcal carriage in children has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevenar (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal, Vaccines, Pneumococcal Conjugate Vaccine | Phase 4 | Status: COMPLETED